OBJECTIVE: To estimate compliance with the 2002 revised perinatal group B streptococci (GBS) prevention guidelines in Tennessee, which recommend universal GBS screening of pregnant women at 35-37 weeks of gestation and, when indicated, administration of intrapartum chemoprophylaxis. METHODS: Active Bacterial Core surveillance conducts active, population-based surveillance for invasive GBS disease in 11 Tennessee counties. A retrospective case-cohort study was conducted using a stratified random sample of all live births in surveillance hospitals during 2003-2004, including all early-onset GBS cases. Factors associated with GBS screening and lack of optimal GBS chemoprophylaxis were analyzed using logistic regression. RESULTS: Screening was performed for 84.7% of pregnant women, but 26.3% of prenatal tests with documented test dates were performed before 35 weeks of gestation. Among women with an indication for GBS prophylaxis, 61.2% received optimal chemoprophylaxis, defined as initiation of a recommended antibiotic 4 hours or more before delivery. When the analysis was restricted to women who were admitted 4 hours or more before delivery, 70.9% received optimal chemoprophylaxis. Women not receiving optimal chemoprophylaxis were more likely to have penicillin allergy (11.7% compared with 2.5%, adjusted odds ratio [OR] 8.58, 95% confidence interval [CI] 1.57-47.04) or preterm delivery (45.5% compared with 13.2%, adjusted OR 5.52, 95% CI 2.29-13.30) and were less likely to have received the recommended prenatal serologic testing for other infectious diseases (77.9% compared with 91.1%, adjusted OR 0.30, 95% CI 0.09-0.98). Forty cases of early-onset GBS were identified (0.36 per 1,000 live births); 25% of these neonates were born to women who received screening at 35 weeks of gestation or later and, when indicated, optimal chemoprophylaxis. CONCLUSION: Universal prenatal GBS screening was implemented widely in Tennessee, although the timing of screening and administration of chemoprophylaxis often were not optimal. A substantial burden of early-onset GBS disease occurs despite optimal prenatal screening and chemoprophylaxis, suggesting that alternative strategies, such as vaccination, are needed. LEVEL OF EVIDENCE: II.
OBJECTIVE: To estimate compliance with the 2002 revised perinatal group B streptococci (GBS) prevention guidelines in Tennessee, which recommend universal GBS screening of pregnant women at 35-37 weeks of gestation and, when indicated, administration of intrapartum chemoprophylaxis. METHODS: Active Bacterial Core surveillance conducts active, population-based surveillance for invasive GBS disease in 11 Tennessee counties. A retrospective case-cohort study was conducted using a stratified random sample of all live births in surveillance hospitals during 2003-2004, including all early-onset GBS cases. Factors associated with GBS screening and lack of optimal GBS chemoprophylaxis were analyzed using logistic regression. RESULTS: Screening was performed for 84.7% of pregnant women, but 26.3% of prenatal tests with documented test dates were performed before 35 weeks of gestation. Among women with an indication for GBS prophylaxis, 61.2% received optimal chemoprophylaxis, defined as initiation of a recommended antibiotic 4 hours or more before delivery. When the analysis was restricted to women who were admitted 4 hours or more before delivery, 70.9% received optimal chemoprophylaxis. Women not receiving optimal chemoprophylaxis were more likely to have penicillinallergy (11.7% compared with 2.5%, adjusted odds ratio [OR] 8.58, 95% confidence interval [CI] 1.57-47.04) or preterm delivery (45.5% compared with 13.2%, adjusted OR 5.52, 95% CI 2.29-13.30) and were less likely to have received the recommended prenatal serologic testing for other infectious diseases (77.9% compared with 91.1%, adjusted OR 0.30, 95% CI 0.09-0.98). Forty cases of early-onset GBS were identified (0.36 per 1,000 live births); 25% of these neonates were born to women who received screening at 35 weeks of gestation or later and, when indicated, optimal chemoprophylaxis. CONCLUSION: Universal prenatal GBS screening was implemented widely in Tennessee, although the timing of screening and administration of chemoprophylaxis often were not optimal. A substantial burden of early-onset GBS disease occurs despite optimal prenatal screening and chemoprophylaxis, suggesting that alternative strategies, such as vaccination, are needed. LEVEL OF EVIDENCE: II.
Authors: Esther Eisenberg; Allen S Craig; Shiva Gautam; Marwa M Khalil; Bashar Shaktour; William Schaffner; Marie R Griffin Journal: Pediatr Infect Dis J Date: 2005-06 Impact factor: 2.129
Authors: Brad D Thigpen; W Ashley Hood; Suneet Chauhan; Laura Bufkin; James Bofill; Everett Magann; John C Morrison Journal: Am J Obstet Gynecol Date: 2005-06 Impact factor: 8.661
Authors: F Y Lin; R A Brenner; Y R Johnson; P H Azimi; J B Philips; J A Regan; P Clark; L E Weisman; G G Rhoads; F Kong; J D Clemens Journal: Am J Obstet Gynecol Date: 2001-05 Impact factor: 8.661
Authors: A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner Journal: Emerg Infect Dis Date: 2001 Jan-Feb Impact factor: 6.883
Authors: Stephanie J Schrag; Elizabeth R Zell; Ruth Lynfield; Aaron Roome; Kathryn E Arnold; Allen S Craig; Lee H Harrison; Arthur Reingold; Karen Stefonek; Glenda Smith; Melanie Gamble; Anne Schuchat Journal: N Engl J Med Date: 2002-07-25 Impact factor: 91.245
Authors: Melissa K Van Dyke; Christina R Phares; Ruth Lynfield; Ann R Thomas; Kathryn E Arnold; Allen S Craig; Janet Mohle-Boetani; Ken Gershman; William Schaffner; Susan Petit; Shelley M Zansky; Craig A Morin; Nancy L Spina; Kathryn Wymore; Lee H Harrison; Kathleen A Shutt; Joseph Bareta; Sandra N Bulens; Elizabeth R Zell; Anne Schuchat; Stephanie J Schrag Journal: N Engl J Med Date: 2009-06-18 Impact factor: 91.245
Authors: Scott A Sullivan; Triz Smith; Eugene Chang; Thomas Hulsey; J Peter Vandorsten; David Soper Journal: Am J Obstet Gynecol Date: 2007-05 Impact factor: 8.661
Authors: Marissa K Person; Douglas H Esposito; Robert C Holman; Jason M Mehal; Barbara J Stoll Journal: Pediatr Infect Dis J Date: 2014-11 Impact factor: 2.129
Authors: Melissa H Spiel; Michele R Hacker; Miriam J Haviland; Bethany Mulla; Elizabeth Roberts; Laura E Dodge; Brett C Young Journal: J Perinatol Date: 2019-01-11 Impact factor: 2.521
Authors: Melissa S Bauserman; Matthew M Laughon; Christoph P Hornik; P Brian Smith; Daniel K Benjamin; Reese H Clark; Cyril Engmann; Michael Cohen-Wolkowiez Journal: Pediatr Infect Dis J Date: 2013-03 Impact factor: 2.129
Authors: Blake W Buchan; Matthew L Faron; DeAnna Fuller; Thomas E Davis; Donna Mayne; Nathan A Ledeboer Journal: J Clin Microbiol Date: 2014-11-19 Impact factor: 5.948
Authors: Mark A Turrentine; Anthony J Greisinger; Kimberly S Brown; Oscar A Wehmanen; Melanie E Mouzoon Journal: Infect Dis Obstet Gynecol Date: 2013-03-28